Keywords: ulcer, study, threat, drug, firms, recently-published, combination
ULCER STUDY NO THREAT TO ULCER DRUG FIRMS
Article | 22 February 1993
The recently-published study of a combination of ranitidine (Glaxo's Zantac) and antibiotics to treat recurrent duodenal ulcers (New England Journal ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
